- Psoriasis sufferers may have an increased risk for abdominal aortic aneurysms.
- The more severe the psoriasis, the greater the risk of developing abdominal aortic aneurysms.
- Psoriasis should be considered an inflammatory state affecting the whole body, rather than an isolated skin disease.
Embargoed until 3 p.m. CT / 4 p.m. ET Thursday, April 14, 2016
DALLAS, April 14, 2016 – Psoriasis sufferers may face a higher risk of developing abdominal aortic aneurysms, according to new research in Arteriosclerosis, Thrombosis and Vascular Biology, an American Heart Association journal.
The study also found that the more severe the psoriasis, the greater the risk for abdominal aortic aneurysms (AAA).
Psoriasis is a chronic autoimmune disease — a condition in which the body’s immune system attacks healthy cells — characterized by patches of abnormal skin. These skin patches are typically red, itchy and scaly. AAA is an enlargement of the main blood vessel that supplies blood to the abdomen, and usually causes no symptoms until it ruptures, which could prove fatal.
“Psoriasis must be considered as a systemic inflammatory disease rather than an isolated skin disease. Increased awareness on heightened risk of other cardiovascular diseases, including AAA, in patients with psoriasis is also required,” said Usman Khalid, M.D., lead author and Ph.D. fellow in the Department of Cardiology, at Herlev and Gentofte Hospital in Denmark.
Using Danish nationwide registers, researchers identified 59,423 patients with mild psoriasis and 11,566 patients with severe psoriasis between 1997 and 2011. These patients were followed until diagnosis of abdominal aortic aneurysms, death, migration or the study end date. The rate of developing abdominal aortic aneurysms (per 10,000 person-years) were:
- 3.72 for general population,
- 7.30 for patients with mild psoriasis, and
- 9.87 for patients with severe psoriasis.
“Compared to the general population, the adjusted incidence rate ratios were significantly increased for severe psoriasis at 1.67. That’s a 67 percent greater risk of AAA likelihood for severe psoriasis sufferers,” Khalid said. “Clinicians need to educate and assist their patients with psoriasis in lifestyle and risk factor modification to facilitate cardiovascular disease risk reduction.”
Khalid said their study adds significantly to current evidence of psoriasis as a clinically relevant risk factor for cardiovascular disease and may require further investigation to answer questions, such as whether patients with psoriasis should undergo increased ultrasonic screening for AAA, and whether anti-inflammatory treatment of psoriasis may reduce the risk of AAA.
Co-authors are Alexander Egeberg, M.D., Ph.D.; Ole Ahlehoff, M.D., Ph.D.; Laerke Smedegaard, M.D.; Gunnar Hilmar Gislason, M.D., Ph.D.; and Peter Riis Hansen, M.D., Ph.D., D.M.Sc. Author disclosures are on the manuscript.
Unrestricted grants from the LEO foundation, and an unrestricted clinical research scholarship from the Novo Nordisk Foundation supported the study. The sponsors had no involvement in study design, no influence on data collection, no access to data, and no influence on decision to submit.
- Researcher photo is located in the right column of this release link http://newsroom.heart.org/news/psoriasis-severity-linked-to-rising-risk-of-abdominal-aortic-aneurysms?preview=48e046d199609592c123d6796600baca
- Severity of skin psoriasis linked to blood vessel inflammation, cardiovascular risk
- Recent asthma may be linked with abdominal aneurysm rupture
- Updated screening policies could detect more abdominal aortic aneurysms
- Follow AHA/ASA news on Twitter @HeartNews.
- For the updates and new science from the Arteriosclerosis, Thrombosis and Vascular Biology journal follow @atvbahajournals.
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association’s policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.
For Media Inquiries and AHA/ASA Spokesperson Perspective: (214) 706-1173
Karen Astle: (214) 706-1392; firstname.lastname@example.org
Julie Del Barto (national broadcast): (214) 706-1330; email@example.com
For Public Inquiries: (800)-AHA-USA1 (242-8721)
Life is why, science is how . . . we help people live longer, healthier lives.